Acceleron Pharma (XLRN)

Revenue in 2021 (TTM): HK$0.87 Billion

According to Acceleron Pharma's latest financial reports the company's current revenue is HK$0.87 Billion. In 2020 the company made a revenue of HK$0.71 Billion an increase over the revenue in the year 2019 that were of HK$0.57 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Acceleron Pharma from 2012 to 2021

Annual revenue

Year	Revenue	Change
2021 (TTM)	HK$0.87 B	21.87%
2020	HK$0.71 B	25.05%
2019	HK$0.57 B	428.85%
2018	HK$0.10 B	3.78%
2017	HK$0.10 B	-51.45%
2016	HK$0.21 B	53.47%
2015	HK$0.14 B	23.68%
2014	HK$0.11 B	-74.43%
2013	HK$0.44 B	275.17%
2012	HK$0.11 B

Revenue for similar companies or competitors

Company	Revenue	Revenue differencediff.	Country
Amgen AMGN	HK$252.78 B	28,751.41%	🇺🇸 USA
Regeneron Pharmaceuticals REGN	HK$107.59 B	12,179.72%	🇺🇸 USA
Johnson & Johnson JNJ	HK$681.39 B	77,669.50%	🇺🇸 USA
Onconova Therapeutics ONTX	HK$1.75 M	-99.80%	🇺🇸 USA
Sangamo Therapeutics SGMO	HK$0.40 B	-53.63%	🇺🇸 USA
bluebird bio BLUE	HK$0.41 B	-52.89%	🇺🇸 USA
Pfizer PFE	HK$467.06 B	53,206.91%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Revenue for Acceleron Pharma (XLRN)

Revenue in 2021 (TTM): HK$0.87 Billion